title: [Half-Dose Verteporfin Photodynamic Therapy (hdPDT) in the Treatment of Central Serous Chorioretinopathy].
abstract: BACKGROUND
  To estimate the efficacy and safety profile of half-dose photodynamic therapy (hdPDT) for treating central serous chorioretinopathy (CSC).
  
  
  METHODS
  An interventional, retrospective case series of patients with CSC (symptoms ≧ 3 months) receiving half-dose PDT (3 mg/m2 verteporfin). The ophthalmic examination at baseline and at 8 and 16 weeks after treatment included slit-lamp biomicroscopy, indirect ophthalmoscopy, measurement of intraocular pressure (IOP), ETDRS best-corrected visual acuity (BCVA), Amsler grid screening and contrast visual acuity (CVA). Fluorescein angiography (FA), autofluorescence (FAF) and optical coherence tomography (OCT) were measured at each visit. Central macular thickness (CMT) was measured automatically.
  
  
  RESULTS
  12 eyes of 12 patients (10 male and 2 female patients; mean age 46.6 ± 7.91 years) were included in this study. Anatomical resolution was obtained in 10 eyes (83.4 %) at week 16, but 2 eyes (16.6 %) exhibited persistent SRD throughout the follow-up period. Baseline CMT decreased from initially 330.1 µm ± 131.3 to 205.6 µm ± 97.6 (p = 0.034) at week 8 and to 220.3 µm ± 120.1 (p = 0.05) at week 16. Visual acuity (number of total letters read) significantly improved from initially 82.8 ± 11.5 to 86.8 ± 13.9 at week 8 and 91.3 ± 13.8 at week 16 (p = 0.012). Contrast visual acuity (calculated decimal visual acuity) significantly improved from initially 0.14 ± 0.09 to 0.38 ± 0.28 (p = 0.002) at week 16. After therapy, no significant changes in RPE could be detected with FAF and no ocular adverse events were observed.
  
  
  CONCLUSIONS
  PDT with half-dose verteporfin resulted in reduced leakage in FA, enhanced visual acuity and resolution of subretinal fluid in OCT in patients with CSC, with no detected side effects of treatment.
authors.affiliation: Klinik für Augenheilkunde, HELIOS Klinikum Pforzheim.
authors.forename: F
authors.initials: F
authors.lastname: Höhn
authors.affiliation: Augenklinik, Universitätsklinikum Heidelberg.
authors.forename: F T A
authors.initials: FT
authors.lastname: Kretz
authors.affiliation: Augenklinik, Universitätsklinikum, Frankfurt.
authors.forename: I
authors.initials: I
authors.lastname: Beger
authors.affiliation: Augenklinik, Universitätsklinikum, Frankfurt.
authors.forename: F
authors.initials: F
authors.lastname: Koch
authors.affiliation: Augenklinik, Universitätsklinikum Heidelberg.
authors.forename: G U
authors.initials: GU
authors.lastname: Auffarth
authors.affiliation: Augenklinik, Universitätsklinikum, Frankfurt.
authors.forename: P
authors.initials: P
authors.lastname: Singh
authors.affiliation: Augenklinik, Universitätsklinikum, Frankfurt.
authors.forename: S
authors.initials: S
authors.lastname: Deuchler
authors.affiliation: Augenklinik, Universitätsklinikum Heidelberg.
authors.forename: M J
authors.initials: MJ
authors.lastname: Koss
mesh_terms: D056833:Central Serous Chorioretinopathy / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000009:adverse effects / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D011166:Porphyrins / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D016896:Treatment Outcome; D000077362:Verteporfin; D014786:Vision Disorders / Q000175:diagnosis / Q000517:prevention & control*; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin